J
Jade Biosciences
Biotechnology company developing novel biologic therapies for autoimmune conditionsand rare diseases
About Jade Biosciences
Jade Biosciences is a biotechnology company focused on developing a pipeline of potentially best-in-class biologics. Engineered by Paragon Therapeutics, a firm founded by leading healthcare investor Fairmount, Jade Biosciences is the fourth company to emerge from Paragon's discovery-stage assets, following Apogee Therapeutics, Spyre Therapeutics,and Oruka Therapeutics. The company operates in the healthcare and biotechnology market, targeting medical professionalsand healthcare providers who require advanced biologic treatments for various medical conditions.
Jade Biosciences' business model revolves around the research, development,and commercialization of innovative biologic therapies. These therapies are designed to address unmet medical needsand improve patient outcomes. The company generates revenue through the sale of its biologic products, licensing agreements,and potential partnerships with other healthcare organizations.
Jade Biosciences prioritizes data protectionand does not sell or rent personally identifiable information to third parties. The company ensures that all support service providers meet stringent data protection standardsand are prohibited from using the information for their own marketing purposes.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2024
- Headquarters
- Waltham, United States
- Listing
- IPO 2024
- Employees
- 81
- Open positions
- 26
- Dealroom signal
- 59.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Oct 2024
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Jun 2026 | $150M | — | Undisclosed | ↗ |
| PRIVATE PLACEMENT NON VCOther financing | Dec 2025 | $45M | — | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Jade Biosciences is 4.8K monthly website visits, down 29.4% over the last three months. Jade Biosciences's team grew 268.2% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later8 investors entered at this stage
Paragon Therapeutics- VPVenrock Healthcare Capital Partners
Fairmount Partners
Franklin Templeton Investments
Deep Track Capital
Braidwell
RTW Investments
Driehaus Capital Management
Other known investors7 additional known investors
Aberdeen
Avidity Partners
Great Point Partners
Janus Henderson Investors
Marshall Wace
RA Capital Management
Samsara BioCapital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Jade Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Jade Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.